Evidence map›Paper›PMID 36530220›Full record

ArticleNeurology. Genetics2023

Severe Cerebral Small Vessel Disease Caused by the Uniallelic p.A252T Variant of

Yasufumi Kondo, Tsuneaki Yoshinaga, Katsuya Nakamura, Tomomi Yamaguchi, Masumi Ishikawa, Tomoki Kosho, Yoshiki Sekijima

Open access · goldAbstract read
In one paragraph

Article in Neurology. Genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yasufumi KondoDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Tsuneaki YoshinagaDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Katsuya NakamuraDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.ORCID https://orcid.org/0000-0003-2342-1089
Tomomi YamaguchiDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Masumi IshikawaDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Tomoki KoshoDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Yoshiki SekijimaDepartment of Medicine (Neurology & Rheumatology) (Y.K., Tsuneaki Yoshinaga, K.N., Y.S.), Shinshu University School of Medicine; Center for Medical Genetics (K.N., Tomomi Yamaguchi, M.I., T.K.), Shinshu University Hospital; Department of Medical Genetics (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine; and Division of Clinical Sequencing (Tomomi Yamaguchi, T.K.), Shinshu University School of Medicine.
Shinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the clinical effect of a heterozygous missense variant of Methods: We performed clinical, laboratory, radiologic, and genetic evaluations of members of a previously reported family with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Results: Two family members were previously reported patients with CARASIL. Among 6 uniallelic p.A252T carriers, 2 had neurologic symptoms with brain MRI abnormalities, 2 showed CSVD on the MRI only, and the other 2 were unaffected. Clinical phenotypes of 2 heterozygous patients were comparable with those of patients with CARASIL, whereas the other 3 heterozygous patients had developed milder and later-onset CSVD. One heterozygous carrier was asymptomatic. Discussion: Previous studies have suggested that uniallelic p.A252T causes disease. However, our study revealed that patients with uniallelic p.A252T can have severe and young-onset CSVD. The clinical manifestations of uniallelic variant carriers were highly variable, even within the same family. Male and atherosclerotic risk factors were considered to be additional factors in the severity of neurologic symptoms in uniallelic p.A252T carriers, suggesting that strict control of vascular risk factors can prevent vascular events in uniallelic

Identifiers

PMID36530220
PMCPMC9756387
OpenAlexW4311803397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.